Summary
Edwards Lifesciences Corporation (EW) presented a strong financial performance in its 2011 10-K filing, demonstrating robust growth across its key business segments. The company's Heart Valve Therapy segment, a core area, showed significant expansion, particularly driven by the growth in transcatheter heart valves and the continued success of its surgical tissue heart valves like the PERIMOUNT Magna series. The Critical Care segment also contributed positively, with advancements in monitoring systems. Geographically, international sales outpaced domestic growth, with Europe and Japan showing notable increases, partly aided by favorable currency exchange rates. The company highlighted its ongoing commitment to research and development, with substantial investments aimed at furthering its leadership in transcatheter technologies and addressing unmet clinical needs in structural heart disease. Despite a challenging regulatory environment and ongoing competition, Edwards Lifesciences maintained a solid financial footing, supported by strategic acquisitions and effective management of its operations.
Financial Highlights
53 data points| Revenue | $1.68B |
| Cost of Revenue | $489.80M |
| Gross Profit | $1.19B |
| R&D Expenses | $246.30M |
| SG&A Expenses | $642.40M |
| Interest Expense | $3.10M |
| Net Income | $236.70M |
| EPS (Basic) | $0.34 |
| EPS (Diluted) | $0.33 |
| Shares Outstanding (Basic) | 687.60M |
| Shares Outstanding (Diluted) | 716.40M |
Key Highlights
- 1Total net sales increased by 16.0% to $1.68 billion in 2011, compared to $1.45 billion in 2010.
- 2Heart Valve Therapy segment sales grew by 20.6% to $1.01 billion, driven by transcatheter heart valves and improved surgical valves.
- 3Transcatheter heart valve sales increased significantly, reflecting growing adoption and market penetration.
- 4International sales showed strong growth of 22.0%, reaching $1.07 billion, with Europe and Japan being key drivers.
- 5Research and Development expenses increased by 20.3% to $246.3 million, emphasizing investment in future growth areas, particularly transcatheter technologies.
- 6The company repurchased $300.1 million of its common stock in 2011, signaling confidence in its financial health and commitment to shareholder value.
- 7A material weakness in internal control over financial reporting was identified related to communication of financial information, leading to restatements of interim financial statements.